Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy

Peking Union Medical College Hospital, Beijing

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

China General Hospital of Shenyang Military Region, Shenyang

Liaoning Province Tumor Hospital, Shenyang

Jilin Cancer Hospital, Changchun

Harbin medical university affiliated tumor hospital, Haerbin

Cancer Hospital of Fudan University, Shanghai

The 81st Hospital of Chinese PLA, Nanjing

Qilu Hospital，Shandong University, Jinan

Tianjin Medical University Cancer Hospital, Tianjin

Chongqing Cancer Hospital, Chongqing

Sun Yat-Sen University Cancer Center, Guangzhou

Guangxi medical university affiliated tumor hospital, Nanning

West China Hospital，Sichuan University, Chengdu

Gansu Province Tumor Hospital, Lanzhou